DIFFERENTIAL EXPRESSION OF FGFRs SIGNALING PATHWAY COMPONENTS IN BLADDER CANCER: A STEP TOWARD PERSONALIZED MEDICINE
Ousati Ashtiani Z, Tavakkoly-Bazzaz J, Salami SA, Pourmand MR, Mansouri F, Mashahdi, Pourmand G1,
*Corresponding Author: Professor Gholamreza Pourmand, Urology Research Center, Sina Hospital, Tehran University Medical Sciences, Hasan Abad Square, Tehran, 113746911, Iran. Tel: +98-216-634-8560. Fax: +98-216-634-8561. Email: pourmand@tums.ac.ir and/ or Associate Professor Javad Tavakkoly-Bazzaz, Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Poursina Street, Tehran, 1417613151, Iran. Tel: +98-218-895-3005. Fax: +98-218-895-3005. Email: tavakkolybazzazj@tums.ac.ir
page: 7

RESULTS

Patient Characteristics. This study comprised 50 BC patients including 43 (86.0%) men and seven (14.0%) women. Analyses of the subjects showed that 36 (72.0%) cases had high-grade and 14 (28.0%) had low-grade tumors. Their median age was 66 years (range 33-84 years). There were 34 patients (68.0%) with a smoking habit, of which 94.0% (32/34) had been cigarette smokers for ≥10 years and 20.0% (10/50) were opium addicts. Of these subjects, 16.0% (8/50) had diabetes and 46.0% (23/50) showed cardiovascular and/or respiratory diseases. The rate of occupational exposure was about 54.0% (27/50). Table 2 shows the demographic and clinicopathological characteristics of all subjects. Increased mRNA expression of FGFR3 was observed in 92.0% (46/50) of tumors. Analysis by a multi variable regression method with a stepwise selection variable demonstrated that there was significant association between increased expression of FGFR3 and cigarette smoking (p = 0.037) and family history of cancer (p = 0.004) (Table 3). We could not find a significant relationship between FGFR3 mRNA over expression and age (p = 0.094) and other relevant clinicopathological parameters including stage, grade and types of the tumor. The comparison of normalized expression in tumor and non tumor tissues showed significant difference (fold change 5.7; p = 0.01) (Figure 1). Unexpectedly, FGFR1 mRNA expression in our BC cases was decreased in 60.0% (30/50) of samples. The majority of high grade tumor (75.0%) (27/36) reflected a significant association with decreased level of FGFR1 mRNA expression (p = 0.047). About 64.2% (9/14) of low-grade tumors showed increased expression of FGFR1. There was also a significant association between normalized expression in tumor vs. non tumor tissue (fold change 4.5; p = 0.01) (Figure 2). Other clinicopathological parameters did not represent any significant difference with FGFR1 expression.



Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006